8-K: Moleculin Reports 2025 Results, AML Trial Data On Track

Moleculin Biotech reported full-year 2025 financial results and confirmed its pivotal MIRACLE trial's 45-patient interim data unblinding is on track for mid-2026, showing encouraging early results in R/R AML.

Summary

• Full-year 2025 financial results reported, with a net loss of $33.56 million, up from $26.048 million in 2024.
• The pivotal Phase 3 MIRACLE trial for Annamycin in relapsed or refractory acute myeloid leukemia (R/R AML) is progressing rapidly.
• Preliminary blinded composite complete remission (CRc) rate of 40% observed in the first 30 subjects treated in the MIRACLE trial, comprising a 30% complete remission (CR) and 10% complete remission with partial hematological recovery (CRh).
• The 45-patient interim data unblinding for the MIRACLE trial is expected in mid-2026.
• Annamycin continues to show an absence of cardiotoxicity, with 90 subjects reviewed by an independent expert.
• New research collaborations for Annamycin in glioblastoma multiforme (GBM) and pancreatic cancer initiated.
• Positive Phase 1 results for WP1066 in pediatric recurrent malignant brain tumors, showing safety and signs of antitumor immune responses.
• Research and development (R&D) expense decreased to $15.9 million in 2025 from $17.7 million in 2024.
• General and administrative (G&A) expenses increased to $9.2 million in 2025 from $8.9 million in 2024.
• Cash and cash equivalents were $8.9 million as of December 31, 2025.
• The company believes cash resources as of December 31, 2025, along with $8.3 million in gross proceeds received via financing activities in the first quarter of 2026, will be sufficient to fund planned operations into the third quarter of 2026.
• Net loss per common share was $(28.42) in 2025, compared to $(189.14) in 2024.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive update due to encouraging early clinical data for Annamycin in a challenging AML population and progress across multiple programs, though tempered by the need for significant future financing.

Positives

• The preliminary blinded CRc rate of 40% in the first 30 MIRACLE trial subjects for R/R AML is encouraging, especially in a pretreated population that includes venetoclax failures.
• Annamycin continues to demonstrate an absence of cardiotoxicity, with 90 subjects reviewed by an independent expert, addressing a common issue with other anthracyclines.
• New research collaborations for Annamycin in glioblastoma multiforme (GBM) and pancreatic cancer expand its potential applications.
• Positive Phase 1 results for WP1066 in pediatric recurrent malignant brain tumors show safety and signs of antitumor immune responses, supporting potential progression to Phase 2.
• Annamycin's Phase 1B/2 trial for soft tissue sarcoma lung metastases showed a median overall survival of 13.5 months in a median seventh-line therapy population, comparing favorably with historical outcomes in earlier-line therapies.
• The company believes it has substantially de-risked the development pathway for Annamycin in AML following a successful Phase 1B/2 study and FDA input.

Negatives

• Net loss increased to $33.56 million in 2025 from $26.048 million in 2024.
• The company will require significant additional financing, for which it has no commitments, to conduct its clinical trials as described.
• Current cash resources, even with Q1 2026 financing, are only sufficient to fund operations into the third quarter of 2026, indicating a short cash runway.
• Significant losses from warrant liabilities (loss on issuance of $30.962 million, transaction costs of $1.407 million, loss on extinguishment of $0.614 million) impacted the net loss.

Risks

• The company will require significant additional financing, for which it has no commitments, to conduct its clinical trials as described in this press release.
• The milestones described in this press release assume the company's ability to secure such financing on a timely basis.
• Expectations reflected in forward-looking statements may prove to have been materially different from the results expressed or implied by such forward-looking statements.
• The dataset referenced in this press release is subject to the review of the data from future subjects in its current and future clinical trials and long-term follow-up with subjects in its current trials.
• Known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. Risk Factors in the most recently filed Form 10-K and updated from time to time in Form 10-Q filings and other public filings with the SEC.

Future Outlook

Moleculin anticipates 2026 will be a defining year, with the pivotal MIRACLE trial's 45-patient interim data unblinding expected in mid-2026. The company projects its current cash resources, supplemented by Q1 2026 financing, will fund operations into the third quarter of 2026. Significant clinical milestones are expected through 2028, including the start of Part B of the MIRACLE trial, new pancreatic cancer studies, and the potential submission of a Rolling New Drug Application (NDA) for R/R AML.

Management Comments

• "With the MIRACLE trial rapidly progressing and the first MIRACLE interim readout now clearly within reach, we believe 2026 will be a defining year for Moleculin."
• "The encouraging blinded efficacy data seen so far, particularly in a pretreated population that includes venetoclax failures, reinforces our belief that Annamycin has the potential to represent a significant advancement in AML therapy."
• "Management believes that cash resources as of December 31, 2025, along with $8.3 million in gross proceeds received via financing activities in the first quarter of 2026 will be sufficient to fund the Company’s planned operations into the third quarter of 2026."
• "Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML."

Industry Context

StockSavvy.ai notes that the R/R AML market represents a significant unmet medical need, particularly for patients who have failed venetoclax regimens. Annamycin's preliminary 40% CRc rate in this challenging population, coupled with its reported absence of cardiotoxicity, positions it as a potentially differentiated treatment option compared to existing anthracyclines which often carry cardiotoxic risks. The expansion into glioblastoma and pancreatic cancer also indicates a broader strategic approach to leverage Annamycin's unique properties across multiple difficult-to-treat oncology indications.

Comparison to Industry Standards

• The preliminary blinded CRc rate of 40% in the MIRACLE trial's first 30 subjects for R/R AML substantially outperforms historical outcomes for CR with cytarabine alone in R/R AML.
• Approximately 35% of treated subjects were relapsed or refractory from a venetoclax regimen, a patient population generally considered among the most challenging to address with second-line therapies.
• Annamycin's Phase 1B/2 trial for soft tissue sarcoma lung metastases demonstrated a median overall survival of 13.5 months in a median seventh-line therapy population, which compares favorably with historical outcomes in earlier-line therapies.
• Annamycin's reported absence of cardiotoxicity, reviewed by an independent expert for 90 subjects, is a key differentiator from currently prescribed anthracyclines like doxorubicin, which are known for cardiotoxic side effects.

Stakeholder Impact

• Shareholders: Potential for increased value if clinical trials continue to show positive results and lead to regulatory approval, but also dilution risk from future capital raises due to the need for significant additional financing.
• Patients (AML, STS, GBM, Pancreatic Cancer): Potential for new, effective, and less cardiotoxic treatment options for hard-to-treat cancers.
• Employees: Continued employment and potential growth opportunities as clinical programs advance.
• Creditors: Risk associated with the company's ongoing net losses and reliance on future financing.

Next Steps

• Mid-2026: Unblinding of 45-subject interim data for the MIRACLE trial.
• Q3 2026: 90 subjects treated and unblinding thereafter for the MIRACLE trial.
• 2H 2026: Start of Part B of the MIRACLE trial.
• 2H 2026: Atlantic Health pancreatic cancer clinical trial begins.
• 2027: Begin recruitment of 3rd line AML subjects.
• 2027: Begin pediatric AML clinical study.
• 2028: End recruitment of Part B of the MIRACLE trial.
• 2028: Primary efficacy data for MIRACLE 2nd line subjects.
• 2028: Begin submission of a Rolling New Drug Application (NDA) for the treatment of R/R AML for accelerated approval.
• Upcoming months: Several important milestones for the WP1066 program.

Key Dates

Recommendation

While the preliminary clinical data for Annamycin in R/R AML is highly encouraging and suggests significant potential, the company's substantial net loss and short cash runway (funding operations only into Q3 2026) present considerable financial risk. The need for significant additional financing without current commitments introduces uncertainty. Investors should hold, awaiting further clarity on financing and the full unblinded interim data from the MIRACLE trial before making further investment decisions.

Keywords

Moleculin Biotech, MBRX, Annamycin, AML, Acute Myeloid Leukemia, MIRACLE trial, R/R AML, Relapsed/Refractory AML, Oncology, Cancer therapy, Clinical trial, Phase 3, Cardiotoxicity, WP1066, Glioblastoma, Pancreatic cancer, Soft tissue sarcoma, Biotechnology, Pharmaceuticals, Drug development, Financial results, SEC filing